Visit our frequently asked questions for more information about InMed’s share consolidation.
Expertise in the pharmaceutical development of rare cannabinoids
InMed is a clinical-stage pharmaceutical company focused on the development of rare cannabinoids to treat several diseases with high unmet medical needs.
Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN), a rare cannabinoid, is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed’s INM-755 is a CBN topical cream under development for epidermolysis bullosa, a devastating, rare genetic skin disease. InMed has completed one of two Phase 1 clinical trials in healthy volunteers. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosa and glaucoma.
InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies support the advancement of INM-755 as an investigational treatment for epidermolysis bullosa (EB) into a Phase 1 clinical study in healthy volunteers, which is currently underway.
While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of them directly from the plant due to the very low quantities available.
IntegraSynTM, InMed’s integrated cannabinoid manufacturing system, uses multiple standard pharmaceutical processes to enable the production of cannabinoids with bio-identical structures as compared to those found in nature.
InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs.
Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.